Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation
- 246 Downloads
Despite improved treatment options, multiple myeloma (MM) remains an incurable disease. The aim of this study was to investigate the prognostic value of positron emission tomography/computed tomography (PET/CT) using 18F-2’-deoxy-2’-fluorodeoxyglucose ([18F]FDG) in MM patients shortly before and ~100 days after allogeneic hematopoietic cell transplantation (allo-HCT).
In this retrospective analysis, we evaluated [18F]FDG-PET/CT-scans of 45 heavily pre-treated MM patients before and 27 patients after scheduled allo-HCT. All scans were qualitatively and semi-quantitatively assessed for the presence of active disease. Serological response was recorded according to International Myeloma Working Group (IMWG) criteria. Progression-free (PFS) and overall survival (OS) were correlated with different PET/CT-derived parameters, such as presence, number and maximum standardized uptake value (SUVmax) of focal myeloma lesions. The impact of extramedullary disease on patient outcome was also assessed.
PET/CT negativity -prior to or following allo-HCT- was a favorable prognostic factor for progression-free and overall survival (both, PFS and OS: pre-HSCT p < 0.001, post-HCT p < 0.005). High FDG-uptake (SUVmax > 6.5) revealed a significantly shortened survival compared to patients with a lower SUVmax (<6.5) (OS, 5.0 ± 1.1 m vs. not reached - longest 122.0 m; p < 0.001). Moreover, our data prove that a higher number (>3) of focal lesions (pre-HCT: both PFS and OS: p < 0.001; post-HCT PFS: p < 0.001, OS: p = 0.139) as well as the presence of extramedullary disease serve as adverse prognostic factors prior to and after allo-HCT. At response assessment after allo-HCT, [18F]FDG-PET/CT had a complementary value in prognostication in addition to IMWG criteria alone.
[18F]FDG-PET/CT before and shortly after allogeneic HCT is a powerful predictor for progression-free and overall survival in MM patients.
KeywordsMultiple myeloma Molecular imaging FDG-PET/CT Allogeneic hematopoietic cell transplantation
Wilhelm Sander-Stiftung, grant 2013.906.1.
Compliance with ethical standards
All procedures involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Disclosure of potential conflict of interest
All authors state that they have nothing to disclose.
- 3.Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schonland S, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT chronic malignancies working party. Leukemia. 2016; https://doi.org/10.1038/leu.2016.101.
- 5.Oostvogels R, Uniken Venema SM, de Witte M, Raymakers R, Kuball J, Kroger N, et al. In search of the optimal platform for post-allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review. Bone Marrow Transplant. 2017;52(9):1233–40. https://doi.org/10.1038/bmt.2017.141.CrossRefPubMedGoogle Scholar
- 7.Durie BG, Waxman AD, D’Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med : Off Publ, Soc Nucl Med. 2002;43(11):1457–63.Google Scholar
- 8.Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters-van den Bos IC, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Brit J Haematol. 2013;162(1):50–61. https://doi.org/10.1111/bjh.12346.CrossRefGoogle Scholar
- 9.Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068–76. https://doi.org/10.1182/blood-2009-03-213280.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med : Off Publ Soc Nucl Med. 2008;49(12):1928–35. https://doi.org/10.2967/jnumed.108.056713.CrossRefGoogle Scholar
- 12.van Lammeren-Venema D, Regelink JC. Riphagen, II, Zweegman S, Hoekstra OS, Zijlstra JM. (1)(8)F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer. 2012;118(8):1971–81. https://doi.org/10.1002/cncr.26467.CrossRefPubMedGoogle Scholar
- 13.Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95. https://doi.org/10.1182/blood-2011-06-361386.CrossRefPubMedGoogle Scholar
- 14.Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819–23. https://doi.org/10.1182/blood-2012-08-451690.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Molec Imaging. 2006;33(5):525–31. https://doi.org/10.1007/s00259-005-0004-3.CrossRefGoogle Scholar
- 16.Nanni C, Zamagni E, Celli M, Caroli P, Ambrosini V, Tacchetti P, et al. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med. 2013;38(2):e74–9. https://doi.org/10.1097/RLU.0b013e318266cee2.CrossRefPubMedGoogle Scholar
- 18.Patriarca F, Carobolante F, Zamagni E, Montefusco V, Bruno B, Englaro E, et al. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1068–73.CrossRefPubMedGoogle Scholar
- 19.Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013:blood-2012-08-451690.Google Scholar
- 20.Lapa C, Luckerath K, Malzahn U, Samnick S, Einsele H, Buck AK, et al. 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget. 2014;5(17):7381–91. https://doi.org/10.18632/oncotarget.2290.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35(25):2911–8. https://doi.org/10.1200/JCO.2017.72.2975.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Tu H, He Y, Huang T, Choe S, Duan X, Sattar H, et al. Predictive value of 18F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma. Eur J Haematol. 2017.Google Scholar